Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two ...

LTI-03 is formulated as a dry powder inhalation therapy that's designed to help ease fibrosis and symptoms of idiopathic ...

Pulmonary fibrosis (PF) is a disease of the respiratory system caused by scarring (fibrosis) in the lungs, which makes it harder for patients to breathe. Based on the underlying cause of the scarring, ...

There is no cure for pulmonary fibrosis (PF), but many therapies are in the pipeline that may be able to slow disease progression, manage symptoms, and improve quality of life for patients. Some of ...

Pulmonary fibrosis (PF) is characterized by scarring, or fibrosis, in the lungs, leading to breathing difficulties, dry cough, muscle aches, and unintended weight loss. Because these symptoms also are ...

Sam Kirton started his column in November 2021 and writes from his home at Lake Anna, Virginia, where he lives with his wife Susan. His diagnosis at age 59 with idiopathic pulmonary fibrosis in ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Respiratory failure is the principle complication of pulmonary fibrosis (PF), leading to a three- to five-year mortality rate for diagnosed patients. Other PF complications include pulmonary arterial ...

PF patients often notice breathlessness when exercising or exerting themselves physically, but as the disease progresses, dyspnea begins to occur even when engaging in simple tasks such as walking, ...